| Domain | Established finding | Evidence type/strength | Key identifier or ontology suggestion |
|---|---|---|---|
| Disease identity | Rare Mendelian neurodevelopmental syndrome defined as **Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies**; disease-target resources link it specifically to **ZMIZ1**. (pqac-00000000, pqac-00000016) | Disease-level curated database association plus foundational primary literature citation | **OMIM 618659**; **EFO_0010659**; suggested MONDO label: ZMIZ1-associated neurodevelopmental disorder |
| Causal gene | Established causal gene is **ZMIZ1** (*zinc finger MIZ-type containing 1*); Open Targets shows this disease associated with **ZMIZ1** only. (pqac-00000000, pqac-00000016) | Curated disease-gene association supported by human primary literature | **ZMIZ1**; **ENSG00000108175** |
| Inheritance | Reported as a dominant developmental disorder largely driven by **de novo** pathogenic variants/rearrangements; practical counseling frame is **mostly de novo autosomal dominant**. (pqac-00000011, pqac-00000016) | Human disease literature and review-level synthesis; moderate confidence | Suggested inheritance term: autosomal dominant; HPO inheritance concept validation recommended |
| Data provenance | Current knowledge is derived from **aggregated disease-level resources** and **small human case reports/series**, not EHR-scale cohorts. (pqac-00000000, pqac-00000016) | Strong resource-level observation | Evidence source class: rare-disease case-series aggregation |
| Core phenotype categories | Core manifestations span **global neurodevelopmental impairment** (ID/developmental delay), **behavioral/neuropsychiatric features** (including ASD/ADHD-related features), **dysmorphic facies**, and **distal skeletal anomalies**; additional reported features may broaden the spectrum. (pqac-00000011, pqac-00000008, pqac-00000013, pqac-00000016) | Human syndrome reports plus broader 2024 synthesis; moderate confidence because exact frequencies were not extracted | Suggested HPO anchors: **Intellectual disability**, **Global developmental delay**, **Autistic behavior**, **Attention deficit hyperactivity disorder**, **Abnormal facial shape**, **Skeletal dysplasia/anomaly of the distal limbs** |
| Onset/course | Disorder is best understood as **congenital/early-childhood onset neurodevelopmental disease** affecting brain development, with persistent developmental and behavioral consequences rather than a remitting course. (pqac-00000010, pqac-00000011) | Indirect but strong developmental-biology support plus human phenotype framing | Suggested HPO anchors: **Congenital onset**, **Developmental delay** |
| Molecular function | ZMIZ1 acts as a **transcriptional co-regulator/co-activator** and **chromatin remodeler-associated factor** rather than a classic DNA-binding transcription factor. (pqac-00000010, pqac-00000015) | Strong mechanistic support from structural/epigenetic analyses and prior literature synthesis | Suggested GO: **transcription coregulator activity**, **chromatin organization**, **positive regulation of transcription by RNA polymerase II** |
| Structural biology | ZMIZ1 is highly constrained for loss-of-function and is enriched for **intrinsically disordered regions** and **linear interacting peptides**, supporting roles in multiprotein complex assembly and regulatory signaling. (pqac-00000010, pqac-00000015) | Strong computational/structural evidence integrated with disease interpretation | Suggested annotations: intrinsically disordered protein; protein complex assembly |
| Chromatin/epigenetic mechanism | ZMIZ1-bound sites are associated with **activating histone marks** (H3K4me1/2/3, H3K9ac, H3K27ac, H3K79me2) and minimal repressive marks, supporting a model of **transcriptional activation/open chromatin regulation**. (pqac-00000010, pqac-00000009, pqac-00000015) | Strong mechanistic evidence from public ChIP/epigenomic analyses | Suggested GO: **histone modification**, **chromatin remodeling**; CHEBI suggestions: **H3K27ac**, **H3K9ac** |
| Developmental expression | ZMIZ1 is **highly expressed in embryonic brain** in mouse and human, then decreases postnatally; enrichment is notable in **cortex, hippocampus, and cerebellum** and in excitatory projection-neuron lineages. (pqac-00000011, pqac-00000010) | Strong expression evidence from public transcriptomic atlases | UBERON: **cerebral cortex**, **hippocampus**, **cerebellum**; CL suggestions: **cortical projection neuron**, **excitatory neuron**, **oligodendrocyte precursor cell**, **astrocyte**, **endothelial cell** |
| Pathophysiology | Best-supported causal chain: **ZMIZ1 dysfunction → altered chromatin/transcriptional regulation during embryonic brain development → impaired neurogenesis, neuronal differentiation, axon/projection development, and synaptic signaling → neurodevelopmental and behavioral phenotypes**. (pqac-00000010, pqac-00000009, pqac-00000008) | Strong multi-layer evidence from mouse transcriptomics and integrated biology; human mechanism remains inferential | Suggested GO: **neurogenesis**, **neuron differentiation**, **axon development**, **synaptic signaling**, **chemical synaptic transmission** |
| Pathway/network context | Interaction/network analyses place ZMIZ1 with **NOTCH1, TP53, SMAD3/4, AR, CTNNB1, CNTNAP2, TBR1, SATB1**, and other neurodevelopmentally relevant factors; synaptic pathways affected include **AMPA receptor activation**, **GABA signaling**, and **neurotransmitter release cycle**. (pqac-00000007, pqac-00000008, pqac-00000009) | Moderate-to-strong systems-level evidence | Suggested pathway tags: **Notch signaling**, **synaptic signaling**, **glutamatergic signaling**, **GABAergic signaling** |
| 2024 mouse model findings | Cortex-specific **Zmiz1 knockout** caused **104 DEGs** at P7, reduced **motor cortical thickness** with significant **layer 6 thinning** at P3, and increased **repetitive behavior** in marble-burying assays; synaptic genes such as **Gria2, Tnc, Cplx3** were downregulated. (pqac-00000009, pqac-00000007, pqac-00000012) | Strong primary in vivo evidence (mouse) from 2024 study | Model type: conditional mouse knockout; GO/CL suggestions: **corticothalamic projection neuron**, **callosal projection neuron** |
| Diagnostic approach | Diagnosis is primarily **molecular**, usually by **exome/genome sequencing** or broad neurodevelopmental disorder testing, with CNV/structural-variant methods relevant because translocations/rearrangements involving ZMIZ1 have also been reported. (pqac-00000016, pqac-00000011) | Strong practice inference from gene-discovery context and structural-variant literature | Suggested tests: **WES**, **WGS**, **trio sequencing**, **chromosomal microarray**, **structural variant analysis** |
| Differential diagnosis | Differential diagnosis includes other **syndromic intellectual disability/autism disorders** with facial and skeletal findings, especially disorders involving transcriptional/chromatin regulators. (pqac-00000011, pqac-00000008) | Indirect but reasonable syndrome-level inference | Suggested ontology grouping: syndromic neurodevelopmental disorder |
| Management | No disease-specific therapy is established; management is **supportive and phenotype-directed**, including developmental surveillance, **speech/occupational/physical therapy**, behavioral/psychiatric care, and organ-system evaluation guided by individual findings. (pqac-00000008, pqac-00000012) | Standard-of-care inference for rare Mendelian NDDs; limited disease-specific outcome data | NCIT suggestions: **Speech Therapy**, **Occupational Therapy**, **Physical Therapy**, **Behavioral Intervention** |
| Prevention/genetic counseling | Primary prevention is not established; after variant identification, families may receive **genetic counseling**, recurrence-risk assessment, and options for **prenatal diagnosis** or **preimplantation genetic testing**. (pqac-00000011, pqac-00000016) | Standard Mendelian-genetics practice inference | NCIT suggestions: **Genetic Counseling**, **Prenatal Genetic Testing**, **Preimplantation Genetic Diagnosis** |
| Epidemiology | **Prevalence, incidence, sex ratio, penetrance, expressivity estimates, carrier frequency, and founder effects are not established** from currently retrieved evidence. (pqac-00000000, pqac-00000016) | Major evidence gap | Evidence-gap flag |
| Variant-level detail | Exact **patient counts, phenotype frequencies, and HGVS-level variant list** from the foundational cohort were not available in retrieved full-text evidence and should not be imputed. (pqac-00000000, pqac-00000016) | Major evidence gap / inaccessible detailed cohort tabulation | Curation priority: retrieve full Carapito et al. 2019 and later case reports |
| Treatments/clinical trials | No disease-specific **approved targeted therapy** or **relevant interventional clinical trial** was identified in the retrieved searches. (pqac-00000000) | Search-based negative finding | Evidence-gap flag; supportive care remains standard |


*Table: This table summarizes the highest-confidence established facts for ZMIZ1-associated neurodevelopmental disorder, including identity, inheritance, mechanism, model evidence, diagnostics, management, and major evidence gaps. It is designed as a compact curation aid for a disease knowledge base.*